Author

Pelin Tokalı

Observed name: Tokalı, Pelin

Institution: Kafkas University

Observed institution: Kafkas University

ORCID: 0000-0002-5553-9543

Observed ORCID: 0000-0002-5553-9543

OpenAlex ID: A5069050774

Synthesis and characterization of novel acyl hydrazones derived from vanillin as potential aldose reductase inhibitors

2022 · Yeliz Demir, Feyzi Sinan Tokalı, et al. · Molecular Diversity · 95

Exploring highly selective polymethoxy fenamate isosteres as novel anti-prostate cancer agents: Synthesis, biological activity, molecular docking, molecular dynamics, and ADME studies

2024 · Feyzi Sinan Tokalı, Halil Şenol, et al. · Journal of Molecular Structure · 55

Development of phenolic Mannich bases as α-glucosidase and aldose reductase inhibitors: In vitro and in silico approaches for managing diabetes mellitus and its complications

2025 · Feyzi Sinan Tokalı, Yeliz Demir, et al. · Bioorganic & Medicinal Chemistry · 47

Design, synthesis, and aldose reductase inhibition assessment of novel Quinazolin-4(3H)-one derivatives with 4-Bromo-2-Fluorobenzene functionality

2025 · Pelin Tokalı, Yeliz Demir, et al. · Bioorganic Chemistry · 41

New Quinazolin‐4(3 H )‐One–Thiazolidine‐2,4‐Dione Hybrids as Dual Inhibitors of α‐Glycosidase and Aldose Reductase: The Synthetic, In Vitro, and In Silico Approaches

2025 · Feyzi Sinan Tokalı, Yeliz Demir, et al. · Journal of Biochemical and Molecular Toxicology · 37

Aldose reductase inhibition properties of novel thiazolidin-2,4-diones: In vitro and in silico approach for the treatment of diabetes-related complications

2025 · Feyzi Sinan Tokalı, Yeliz Demir, et al. · Journal of Molecular Liquids · 37

Quinazolin‐4(3 H )‐One‐Based New Glitazones as Dual Inhibitors of α‐Glucosidase and Aldose Reductase: Comprehensive Approaches for Managing Diabetes Mellitus and Its Complications

2025 · Feyzi Sinan Tokalı, Yeliz Demir, et al. · Archiv der Pharmazie · 34

Design and synthesis of new thienopyrimidine derivatives as potential anticancer agents: From cytotoxicity screening to VEGFR inhibition modeling

2025 · Feyzi Sinan Tokalı, Halil Şenol, et al. · Journal of Molecular Structure · 20

2‐Propyl‐3‐Aminoquinazoline‐4(3 H )‐one Derivatives as Potential Androgen Receptor Inhibitors: Synthesis and Cytotoxicity Against PC3 Cell Line via In Vitro and In Silico Studies

2025 · Halil Şenol, Furkan Çakır, et al. · Archiv der Pharmazie · 17

Synthesis, Characterization and In Vitro and In Silico Biological Evaluation of New Mannich-Based Rhodanine and Thiazolidine-2,4-dione Derivatives as Potential Anti-Lung-Cancer Agents

2025 · Halil Şenol, Feyzi Sinan Tokalı, et al. · Synlett · 11

New quinazolinone-thiazolidinedione hybrids as selective anti-lung cancer agents and promising EGFR inhibitors

2026 · Pelin Tokalı, Ayşe Merve Şenol, et al. · Future Medicinal Chemistry · 10

Design and synthesis of Polymethoxy Rhodanines as selective small-molecule candidates for breast cancers

2026 · Feyzi Sinan Tokalı, Gurbet Çelik Turgut, et al. · Journal of Molecular Structure · 6

Development of novel diaryl ether–phenolic Mannich Base derivatives with potent cholinesterase inhibition and low neuronal toxicity

2026 · Halil Şenol, Yeliz Demir, et al. · Bioorganic Chemistry · 5

Rational design of thiazolidine-2,4-dione-integrated combretastatin A-4 analogues as potent and selective tubulin-targeting agents for triple-negative breast cancer

2026 · Feyzi Sinan Tokalı, Şeyma Ateşoğlu, et al. · European Journal of Medicinal Chemistry · 1

New quinazolinone-thiazolidinedione hybrids as selective anti-lung cancer agents and promising EGFR inhibitors

2026 · Tokalı, Pelin, Şenol, Ayşe Merve, et al. · Figshare

Works count: 15

Citation count: 416

H-index: 10

I10-index: 11